tbuckley/cabot-search huggingface dataset:
Abstract P3-12-03: Pre-diagnostic plasma 25-hydroxyvitamin D and mortality among women with breast cancer in the nurses’ health study cohorts
Authors: Etienne Holder
Journal: Cancer Research (2022)

Abstract Background: Sufficient levels of vitamin D are critical for optimal health. 25-hydroxyvitamin D (25(OH)D) is an essential steroid hormone, derived from sun exposure, diet, and supplement use, that is hypothesized to influence breast cancer prognosis by inhibiting breast tumor growth. While this has been observed in laboratory-based studies, findings from observational studies are inconclusive. We examined the association between pre-diagnostic 25(OH)D concentrations and both breast cancer-specific and overall mortality to explore the potential effects of vitamin D, a modifiable exposure. Methods: We evaluated the association between pre-diagnostic plasma 25(OH)D concentrations and breast cancer-specific and total mortality among 1,300 women diagnosed with invasive, non-metastatic breast cancer enrolled in the Nurses’ Health Study 1 (NHS1) and Nurses’ Health Study 2 (NHS2) cohorts. In this analysis, women provided a blood sample from 1989-1990 and a second blood sample in 2000-2001 (NHS1) or a blood sample from 1996-1999 (NHS2). Women were diagnosed with breast cancer after blood collection up through 2016 (NHS1) and 2017 (NHS2) and censored at end of study (2016 NHS1; 2017 NHS2) or death, whichever came first. Cox proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals (95%CI) for mortality after adjustment for tumor characteristics, type of cancer treatment, and lifestyle factors. For women with two blood samples, most recent exposure status was used in the analyses. Results: A total of 396 total deaths and 145 breast cancer-specific deaths occurred during follow-up through 2017. We observed a non-statistically significant 25% lower breast cancer-specific mortality rate among those with the highest, versus lowest, quartile of pre-diagnostic 25(OH)D levels (HRQ4vsQ1 0.75, 95%CI 0.45-1.25; p for trend=0.32), that did not vary significantly by estrogen receptor status of the tumor (p for interaction=0.61). Women in the highest vs. lowest quartile of plasma 25(OH)D experienced a 31% lower overall mortality rate (HRQ4vsQ1 0.69, 95%CI 0.51-0.93; p for trend=0.03). In cause-specific mortality analyses among non-breast cancer deaths, non-statistically significant decreases were observed for other cancer deaths and cardiovascular disease deaths. Conclusion: Pre-diagnostic plasma 25(OH)D levels were not significantly associated with lower breast cancer-specific mortality among women with breast cancer. However, significant inverse associations were observed for total mortality, which supports a potential benefit of vitamin D among these women. Citation Format: Etienne Holder. Pre-diagnostic plasma 25-hydroxyvitamin D and mortality among women with breast cancer in the nurses’ health study cohorts [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P3-12-03.
VENTRICULAR TACHYCARDIA PRIOR TO CONTINUOUS FLOW LEFT VENTRICULAR ASSIST DEVICE IMPLANTATION WAS NOT ASSOCIATED WITH REDUCED SURVIVAL: A SINGLE CENTER EXPERIENCE
Authors: Peter Rothstein, Summit Pandat, Rachel Laird, Momin Islam, Amy Truman, Syed Zaid, Arvind Bhimaraj, Rayan Yousefzai, Paul Schurmann, Amish S. Dave, Miguel Valderrabano, Nilesh Mathuria
Journal: Journal of the American College of Cardiology (2022)
The risk of hyperglycaemia associated with the use of dolutegravir among adults living with HIV in Kampala, Uganda: a case-control study
Authors: Daphine Namara, Jeremy I Schwartz, Andrew K Tusubira, Willi McFarland, Caroline Birungi, Fred C Semitala, Martin Muddu
Journal: The Lancet Global Health (2022)

Emerging evidence suggests a possible association between hyperglycaemia and use of dolutegravir, a preferred first-line antiretroviral agent in sub-Saharan Africa. Rigorous studies are needed to validate this association in the light of increasing dolutegravir use and burden of non-communicable diseases among people living with HIV.We conducted a case-control study in Kampala, Uganda to assess the risk of hyperglycaemia associated with dolutegravir-based antiretroviral therapy (ART). Cases were people living with HIV with hyperglycaemia and controls were people living with HIV without hyperglycaemia, confirmed by fasting plasma glucose and 2-hour oral glucose tolerance tests. Data were collected by interviewer-administered questionnaires and medical record abstraction. Analysis compared cases and controls on dolutegravir use before diagnosis of hyperglycaemia while controlling for potential confounders through multivariable logistic regression.A total 435 participants were included (204 cases, 231 controls). At bivariate analysis, significant differences in age, education, current body-mass index, hypertension as a comorbidity, previous ART regimen, and current ART regimen existed between cases and controls. Among the 204 cases, 54 (27%) had hyperglycaemic levels that were diagnostic of prediabetes, with 150 (74%) being diagnostic of diabetes. Of note, 75 (40%) participants previously treated with dolutegravir changed to other ART regimens after being diagnosed with hyperglycaemia. In multivariable analysis, patients with previous dolutegravir use had nearly 30-times greater odds of hyperglycaemia compared with those who had non-dolutegravir based regimens (adjusted odds ratio [aOR] 29·06 [95% CI 9·86-85·70]). The odds of hyperglycaemia also increased with age (56 years and older vs 18-35 years, aOR 7·53 [95% CI 2·65-21·38]), and hypertension (aOR 5·64 [2·60-12·21]).Our study shows a strong association between previous dolutegravir exposure and hyperglycaemia. Given the benefits of dolutegravir, its wide-scale roll-out in sub-Saharan Africa, and the growing burden of diabetes, systematic screening of hyperglycaemia before initiation of dolutegravir, routine glucose monitoring, and the consideration of alternate regimens for those at risk for diabetes are needed.This research was supported by the US National Institutes of Health, Fogarty International Center and Global Health Equity Scholars (grant D43TW010540).
Linking the genotypes and phenotypes of cancer cells in heterogenous populations via real-time optical tagging and image analysis
Authors: Li You, Pin-Rui Su, Max Betjes, Reza Ghadiri Rad, Ting-Chun Chou, Cecile Beerens, Eva van Oosten, Felix Leufkens, Paulina Gasecka, Mauro Muraro, Ruud van Tol, Debby van Steenderen, Shazia Farooq, Jose Angelito U. Hardillo, Robert Baatenburg de Jong, Daan Brinks, Miao-Ping Chien
Journal: Nature Biomedical Engineering (2022)
IMPACT OF PHYSICAL FRAILTY ON SURVIVAL AND QUALITY OF LIFE IN HEART FAILURE PATIENTS
Authors: Joseph Somech, Aayushi Joshi, Rita Mancini, Jessica Chetrit, Caroline Michel, Richard J. Sheppard, Viviane Nguyen, Mathieu A. Walker, Nadia Gianetti, Abhinav Sharma, Esther Laforest, Delina Maghakian, Jonathan Afilalo
Journal: Journal of the American College of Cardiology (2022)
Assessing the role of stressful life events in the induction and recurrence of alopecia areata: A case-control study
Authors: Panagiotis Ferentinos, Eugenia Kalogeropoulou, Georgia Pappa, Anastasia Antoniou, Evangelia Bozi, Miltiades Kyprianou, Dimitrios Rigopoulos, Alexandros C. Katoulis
Journal: Journal of the American Academy of Dermatology (2022)
Acids produced by lactobacilli inhibit the growth of commensal <i>Lachnospiraceae</i> and S24-7 bacteria
Authors: Emma J. E. Brownlie, Danica Chaharlangi, Erin Oi-Yan Wong, Deanna Kim, William Wiley Navarre
Journal: Gut Microbes (2022)

The Lactobacillaceae are an intensively studied family of bacteria widely used in fermented food and probiotics, and many are native to the gut and vaginal microbiota of humans and other animals. Various studies have shown that specific Lactobacillaceae species produce metabolites that can inhibit the colonization of fungal and bacterial pathogens, but less is known about how Lactobacillaceae affect individual bacterial species in the endogenous animal microbiota. Here, we show that numerous Lactobacillaceae species inhibit the growth of the Lachnospiraceae family and the S24-7 group, two dominant clades of bacteria within the gut. We demonstrate that inhibitory activity is a property common to homofermentative Lactobacillaceae species, but not to species that use heterofermentative metabolism. We observe that homofermentative Lactobacillaceae species robustly acidify their environment, and that acidification alone is sufficient to inhibit growth of Lachnospiraceae and S24-7 growth, but not related species from the Clostridiales or Bacteroidales orders. This study represents one of the first in-depth explorations of the dynamic between Lactobacillaceae species and commensal intestinal bacteria, and contributes valuable insight toward deconvoluting their interactions within the gut microbial ecosystem.
A SYSTEMATIC REVIEW OF MYOCARDITIS FOLLOWING COVID-19 VACCINATION
Authors: Vinh S. Dong, Omar Makram, Quyen Dinh, Thang Tran, Abdelrahman M Makram, An Thanh Nguyen, Tasnim Ali, Sarah Brown, Kevin Moriles, Juan Castillo, Nguyen Tien Huy
Journal: Journal of the American College of Cardiology (2022)
THE EFFECT OF CSL112 (APOLIPOPROTEIN A-I, HUMAN) ON CHOLESTEROL EFFLUX CAPACITY: A CROSS-STUDY COMPARISON
Authors: Bo Zheng, Shinya Goto, Regina Clementi, John Feaster, Danielle Duffy, Penelope Dalitz, Jolanta Airey, John Roberts, Serge Korjian, Michael C. Gibson
Journal: Journal of the American College of Cardiology (2022)
CARDIAC AMYLOIDOSIS: A CAUSE OF DIASTOLIC HEART FAILURE WITH RELATIVELY NORMAL LEFT VENTRICULAR WALL THICKNESS
Authors: William Sanchez-Garcia, Amudhan Jyothidasan, Amol A. Bahekar, Gunjan S. Joshi, Haitham Mazek, Manoj Bhandari
Journal: Journal of the American College of Cardiology (2022)
IMPACT OF THE 2018 UNOS HEART ALLOCATION POLICY CHANGE ON POST-TRANSPLANT OUTCOMES: INTERMEDIATE TERM ANALYSIS
Authors: Eugene Christopher DePasquale, Jonathan Nattiv, Kruti Ameesh Pandya, Michael Fong, Anahat Dhillon, Lee Raymond, Mark J. Cunningham, Aaron Wolfson, Ajay Vaidya
Journal: Journal of the American College of Cardiology (2022)
The niacin receptor HCAR2 modulates microglial response and limits disease progression in a mouse model of Alzheimer’s disease
Authors: Miguel Moutinho, Shweta S. Puntambekar, Andy P. Tsai, Israel Coronel, Peter B. Lin, Brad T. Casali, Pablo Martinez, Adrian L. Oblak, Cristian A. Lasagna-Reeves, Bruce T. Lamb, Gary E. Landreth
Journal: Science Translational Medicine (2022)

Increased dietary intake of niacin has been correlated with reduced risk of Alzheimer’s disease (AD). Niacin serves as a high-affinity ligand for the receptor HCAR2 (GPR109A). In the brain, HCAR2 is expressed selectively by microglia and is robustly induced by amyloid pathology in AD. The genetic inactivation of Hcar2 in 5xFAD mice, a model of AD, results in impairment of the microglial response to amyloid deposition, including deficits in gene expression, proliferation, envelopment of amyloid plaques, and uptake of amyloid-β (Aβ), ultimately leading to exacerbation of amyloid burden, neuronal loss, and cognitive deficits. In contrast, activation of HCAR2 with an FDA-approved formulation of niacin (Niaspan) in 5xFAD mice leads to reduced plaque burden and neuronal dystrophy, attenuation of neuronal loss, and rescue of working memory deficits. These data provide direct evidence that HCAR2 is required for an efficient and neuroprotective response of microglia to amyloid pathology. Administration of Niaspan potentiates the HCAR2-mediated microglial protective response and consequently attenuates amyloid-induced pathology, suggesting that its use may be a promising therapeutic approach to AD that specifically targets the neuroimmune response.
SIGNIFICANT DISCREPANCY IN BRACHIAL TO FEMORAL SYSTOLIC BLOOD PRESSURES AS AN INCIDENTAL FINDING OF SEVERE ATHEROSCLEROTIC STENOSIS OF THE PROXIMAL ABDOMINAL AORTA IN AN ASYMPTOMATIC PATIENT
Authors: Dilesha Kumanayaka, Asrar Ahmad, Jasjit Walia
Journal: Journal of the American College of Cardiology (2022)
Neural correlates of blood flow measured by ultrasound
Authors: Anwar O. Nunez-Elizalde, Michael Krumin, Charu Bai Reddy, Gabriel Montaldo, Alan Urban, Kenneth D. Harris, Matteo Carandini
Journal: Neuron (2022)

Functional ultrasound imaging (fUSI) is an appealing method for measuring blood flow and thus infer brain activity, but it relies on the physiology of neurovascular coupling and requires extensive signal processing. To establish to what degree fUSI trial-by-trial signals reflect neural activity, we performed simultaneous fUSI and neural recordings with Neuropixels probes in awake mice. fUSI signals strongly correlated with the slow (<0.3 Hz) fluctuations in the local firing rate and were closely predicted by the smoothed firing rate of local neurons, particularly putative inhibitory neurons. The optimal smoothing filter had a width of ∼3 s, matched the hemodynamic response function of awake mice, was invariant across mice and stimulus conditions, and was similar in the cortex and hippocampus. fUSI signals also matched neural firing spatially: firing rates were as highly correlated across hemispheres as fUSI signals. Thus, blood flow measured by ultrasound bears a simple and accurate relationship to neuronal firing.
ENHANCED WEARABILITY EXPERIENCE AND ACCURACY OF A NOVEL FDA-VALIDATED NONINVASIVE AMBULATORY ECG DEVICE COMPARED WITH A CONVENTIONAL HOLTER MONITOR: THE QARDIO-ECG STUDY
Authors: Andrea Cardona, Thura T. Harfi, Haikady N. Nagaraja, Matthew Tong, Ugo Paliani
Journal: Journal of the American College of Cardiology (2022)
REFINING MURRAY’S LAW IN HUMAN EPICARDIAL CORONARY ARTERIES
Authors: Daniel Taylor, Paul David Morris, Julian Gunn, Rebecca Gosling, Ian Halliday, Vignesh Rammohan, David R. Hose, Pim A. Tonino, Daniëlle Keulards, Jeroen Feher, Michel Rochette, Marcel van‘t Veer
Journal: Journal of the American College of Cardiology (2022)
Metabolomic profiling reveals extensive adrenal suppression due to inhaled corticosteroid therapy in asthma
Authors: Priyadarshini Kachroo, Isobel D. Stewart, Rachel S. Kelly, Meryl Stav, Kevin Mendez, Amber Dahlin, Djøra I. Soeteman, Su H. Chu, Mengna Huang, Margaret Cote, Hanna M. Knihtilä, Kathleen Lee-Sarwar, Michael McGeachie, Alberta Wang, Ann Chen Wu, Yamini Virkud, Pei Zhang, Nicholas J. Wareham, Elizabeth W. Karlson, Craig E. Wheelock, Clary Clish, Scott T. Weiss, Claudia Langenberg, Jessica A. Lasky-Su
Journal: Nature Medicine (2022)
Lung Cancer in Sudan
Authors: Moawia Mohammed Ali Elhassan, Ahmed Abdalla Mohamedani, Sahar Abdelrahman Hamid Mohamed, Anas Osman Ahmed Hamdoun, Dafalla Omer Abuidris, Alsideeg Mohammed Alamin Mohammed, Khalid Dafaallah Awadelkarim
Journal: Journal of Thoracic Oncology (2022)
Maternal-Fetal Therapy: The (Psycho)Social Dilemma
Authors: Neeltje Crombag, Daniel Pizzolato, Jan Deprest, Kris Dierickx
Journal: The American Journal of Bioethics (2022)

This article is referred to by:A New Ethical Framework for Assessing the Unique Challenges of Fetal Therapy Trials: Response to CommentariesFetal Therapies and Clinical Research: Beyond Risk and BenefitWhat Lies Beneath the Framework: The Importance of Grounding Ethical Discussions of Maternal-Fetal Therapy
CLINICAL PREDICTORS OF RATE CONTROL THERAPY IN PATIENTS WITH ATRIAL FIBRILLATION ACROSS RACE-ETHNICITY
Authors: Baha’A Al-azzam, Katherine Shapiro, David Tofovic, Victor Qiao, Aylin Ornelas, Yining Chen, Sreenivas Konda, Dawood Darbar
Journal: Journal of the American College of Cardiology (2022)
One-off low-dose CT for lung cancer screening in China: a multicentre, population-based, prospective cohort study
Authors: Ni Li, Fengwei Tan, Wanqing Chen, Min Dai, Fei Wang, Sipeng Shen, Wei Tang, Jiang Li, Yiwen Yu, Wei Cao, Yongjie Xu, Chao Qin, Liang Zhao, Meng Zhu, Lanwei Guo, Zheng Wu, Zhuoyu Yang, Yadi Zheng, Hongda Chen, Yunyong Liu, Donghua Wei, Dong Dong, Ji Cao, Shaokai Zhang, Shipeng Yan, Ning Wang, Lingbin Du, Hongbing Shen, Ning Wu, Jie He, Ji Cao, Sumei Cao, Wei Cao, Hongda Chen, Wanqing Chen, Ying Cheng, Hong Cui, Min Dai, Dong Dong, Hua Dong, Xuesi Dong, Lingbin Du, Lianying Ge, Jiyong Gong, Lanwei Guo, Jie He, Mei He, Yutong He, Limin Huang, Yao Huang, Yubei Huang, Yunchao Huang, Jing Jiang, Shengyan Jin, Yunxin Kong, Fang Li, Jiang Li, Jibin Li, Ni Li, Xin Li, Xianzhen Liao, Yunyong Liu, Yuqin Liu, Zilin Luo, Zhangyan Lv, Hongxia Ma, Yanling Ma, Liang Qiao, Chao Qin, Jiansong Ren, Hongbing Shen, Sipeng Shen, Jufang Shi, Benhua Song, Bingbing Song, Shuming Song, Kai Su, Gang Sun, Fengwei Tan, Wei Tang, Fei Wang, Le Wang, Ning Wang, Donghua Wei, Luopei Wei, Qingfeng Wei, Yan Wen, Ning Wu, Zheng Wu, Yunfeng Xi, Yongjie Xu, Shipeng Yan, Lei Yang, Zhuoyu Yang, Zhihua Yin, Lianzheng Yu, Xinyang Yu, Yiwen Yu, Min Zhang, Shaokai Zhang, Yongzhen Zhang, Liang Zhao, Yadi Zheng, Baosen Zhou, Jinyi Zhou, Chen Zhu, Meng Zhu, Kaiyong Zou
Journal: The Lancet Respiratory Medicine (2022)
PREVALENCE OF STRUCTURAL ECHOCARDIOGRAPHIC ABNORMALITIES IN PATIENTS WITH TYPE 2 DIABETES IN PRIMARY CARE: INSIGHTS FROM THE TAKE CARE OF ME PROGRAMME IN 4 EMERGING COUNTRIES
Authors: Kamlesh Khunti, Shashank Joshi, Peter Fenici, Larisa Ramirez, Alejandra Silva, Filip Arnold M. Surmont, Hiddo Heerspink, Mikhail Kosiborod, Carolyn S.P. Lam, Antonio Nicolucci, Hardik Vasnawala, Estefania Vazquez
Journal: Journal of the American College of Cardiology (2022)
Correspondence on ‘2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis’ by Joanna C Robson<i>et al</i>and ‘2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis’
Authors: Victor Román Pimentel-Quiroz, Manuel Francisco Ugarte-Gil, Graciela S Alarcón
Journal: Annals of the Rheumatic Diseases (2022)

College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis' by Ravi Suppiah et
Association of computed tomography screening with lung cancer stage shift and survival in the United States: quasi-experimental study
Authors: Alexandra L Potter, Allison L Rosenstein, Mathew V Kiang, Shivani A Shah, Henning A Gaissert, David C Chang, Florian J Fintelmann, Chi-Fu Jeffrey Yang
Journal: BMJ (2022)

To determine the effect of the introduction of low dose computed tomography screening in 2013 on lung cancer stage shift, survival, and disparities in the stage of lung cancer diagnosed in the United States.Quasi-experimental study using Joinpoint modeling, multivariable ordinal logistic regression, and multivariable Cox proportional hazards modeling.US National Cancer Database and Surveillance Epidemiology End Results program database.Patients aged 45-80 years diagnosed as having non-small cell lung cancer (NSCLC) between 1 January 2010 and 31 December 2018.Annual per cent change in percentage of stage I NSCLC diagnosed among patients aged 45-54 (ineligible for screening) and 55-80 (potentially eligible for screening), median all cause survival, and incidence of NSCLC; multivariable adjusted odds ratios for year-to-year changes in likelihood of having earlier stages of disease at diagnosis and multivariable adjusted hazard ratios for changes in hazard of death before versus after introduction of screening.The percentage of stage I NSCLC diagnosed among patients aged 55-80 did not significantly increase from 2010 to 2013 (from 27.8% to 29.4%) and then increased at 3.9% (95% confidence interval 3.0% to 4.8%) per year from 2014 to 2018 (from 30.2% to 35.5%). In multivariable adjusted analysis, the increase in the odds per year of a patient having one lung cancer stage lower at diagnosis during the time period from 2014 to 2018 was 6.2% (multivariable adjusted odds ratio 1.062, 95% confidence interval 1.048 to 1.077; P<0.001) higher than the increase in the odds per year from 2010 to 2013. Similarly, the median all cause survival of patients aged 55-80 did not significantly increase from 2010 to 2013 (from 15.8 to 18.1 months), and then increased at 11.9% (8.9% to 15.0%) per year from 2014 to 2018 (from 19.7 to 28.2 months). In multivariable adjusted analysis, the hazard of death decreased significantly faster after 2014 compared with before 2014 (P<0.001). By 2018, stage I NSCLC was the predominant diagnosis among non-Hispanic white people and people living in the highest income or best educated regions. Non-white people and those living in lower income or less educated regions remained more likely to have stage IV disease at diagnosis. Increases in the detection of early stage disease in the US from 2014 to 2018 led to an estimated 10 100 averted deaths.A recent stage shift toward stage I NSCLC coincides with improved survival and the introduction of lung cancer screening. Non-white patients and those living in areas of greater deprivation had lower rates of stage I disease identified, highlighting the need for efforts to increase access to screening in the US.
M6A RNA Methylation Regulates Histone Ubiquitination to Support Cancer Growth and Progression
Authors: Pooja Yadav, Panneerdoss Subbarayalu, Daisy Medina, Saif Nirzhor, Santosh Timilsina, Subapriya Rajamanickam, Vijay K. Eedunuri, Yogesh Gupta, Siyuan Zheng, Nourhan Abdelfattah, Yufei Huang, Ratna Vadlamudi, Robert Hromas, Paul Meltzer, Peter Houghton, Yidong Chen, Manjeet K. Rao
Journal: Cancer Research (2022)

Abstract Osteosarcoma is the most common malignancy of the bone, yet the survival for patients with osteosarcoma is virtually unchanged over the past 30 years. This is principally because development of new therapies is hampered by a lack of recurrent mutations that can be targeted in osteosarcoma. Here, we report that epigenetic changes via mRNA methylation holds great promise to better understand the mechanisms of osteosarcoma growth and to develop targeted therapeutics. In patients with osteosarcoma, the RNA demethylase ALKBH5 was amplified and higher expression correlated with copy-number changes. ALKBH5 was critical for promoting osteosarcoma growth and metastasis, yet it was dispensable for normal cell survival. Methyl RNA immunoprecipitation sequencing analysis and functional studies showed that ALKBH5 mediates its protumorigenic function by regulating m6A levels of histone deubiquitinase USP22 and the ubiquitin ligase RNF40. ALKBH5-mediated m6A deficiency in osteosarcoma led to increased expression of USP22 and RNF40 that resulted in inhibition of histone H2A monoubiquitination and induction of key protumorigenic genes, consequently driving unchecked cell-cycle progression, incessant replication, and DNA repair. RNF40, which is historically known to ubiquitinate H2B, inhibited H2A ubiquitination in cancer by interacting with and affecting the stability of DDB1-CUL4–based ubiquitin E3 ligase complex. Taken together, this study directly links increased activity of ALKBH5 with dysregulation of USP22/RNF40 and histone ubiquitination in cancers. More broadly, these results suggest that m6A RNA methylation works in concert with other epigenetic mechanisms to control cancer growth. Significance: RNA demethylase ALKBH5 upregulates USP22 and RNF40 to inhibit histone H2A ubiquitination and induces expression of key replication and DNA repair–associated genes, driving osteosarcoma progression.
Single-cell RNA sequencing of mast cells in eosinophilic esophagitis reveals heterogeneity, local proliferation, and activation that persists in remission
Authors: Netali Ben-Baruch Morgenstern, Adina Y. Ballaban, Ting Wen, Tetsuo Shoda, Julie M. Caldwell, Kara Kliewer, Jennifer M. Felton, J. Pablo Abonia, Vincent A. Mukkada, Philip E. Putnam, Scott M. Bolton, Daniel F. Dwyer, Nora A. Barrett, Marc E. Rothenberg
Journal: Journal of Allergy and Clinical Immunology (2022)